Polyrizon Ltd.
PLRZ · NASDAQ
Market closed$13.42$0.420000 (+3.23%)After hours $13.04 · -2.83%
Key statistics
Previous close$13.00
Open$12.47
Day high$13.42
Day low$12.47
52-week high$18.20
52-week low$2.88
Market cap15.03M
Volume8.29K
Average volume44.53K
P/E ratio-6.85
Forward P/E—
EPS-1.96
Dividend yield0.00%
Market context
Why it moved
PLRZ shares moved higher likely in sympathy with positive momentum among small-cap biotech and healthcare peers, as broader sector sentiment improved amid encouraging clinical trial news from related companies in the space.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 13, 2026Polyrizon (PLRZ) locks in 3-year executive and director pay policyPluang · July 2, 2026Polyrizon's NASARIX nasal spray passes biocompa...Investing.com · July 2, 2026Polyrizon stock rises on biocompatibility test resultsStock Titan · June 29, 2026Polyrizon clears review to start first NASARIX human allergy trialQuiver Quantitative · June 29, 2026Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy BlockerStock Titan · June 8, 2026New nasal gel trial to block airborne seasonal allergens in U.S.Stock Titan · April 8, 2026Polyrizon raises $3.5M in stock sale for working capitalSimply Wall Street · March 28, 2026We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate Benzinga · July 2, 2026Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial Mt Newswire · July 2, 2026Polyrizon Says Nasarix Allergy Nasal Spray Meets All Biocompatibility Safety Standards in Testing Mt Newswire · June 29, 2026Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis Benzinga · June 29, 2026Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens Mt Newswire · June 15, 2026Polyrizon Signs Agreements for Nasarix Human Study Benzinga · June 15, 2026Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker's Nasal Residence Time Benzinga · June 10, 2026Polyrizon Announces European Patent Office To Publish The Company's Application 'Mucoadhesive Polymers For Nasal Drug Delivery' Mt Newswire · June 8, 2026Polyrizon Advances Nasarix Study With 3 Major US Trial Sites